SL

Simulations Plus, Inc.

SLPHealthcareNASDAQ

Health Information Services

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$79.2M
+13.1% YoY
Net Income
-$64.7M
-750.2% YoY
EBITDA
$14.7M
+24.6% YoY
Free Cash Flow
$18.4M

Scan Results

Daily timeframe
DateIndicatorDetails
Jul 8CONFIRMED RSI OverboughtRSI 86.3, above 70, stock may be overbought
MACD Negative CrossoverHistogram -0.0497, negative momentum
Jul 7CONFIRMED RSI OverboughtRSI 89.2, above 70, stock may be overbought
MACD Negative CrossoverHistogram -0.0269, negative momentum
About Simulations Plus, Inc.

Headquartered within the healthcare sector, Simulations Plus, Inc. focuses on Health Information Services services and products. Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The $368.7M market capitalization puts SLP squarely in small-cap range for its industry. It operates through Software and Services segments.

Key stats
Market Cap$368.7M
P/E (TTM)45.58
Fwd P/E20.66
EPS$0.40
Beta1.31
52W Change+46.3%
ROE6.2%
Analysis

With $50.0M in cash and $487K in debt, SLP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $18.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 6.2% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $53.9M (2022) to $79.2M (2025), reflecting a 47% increase over the period.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SLP.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms